CDK4 and breast carcinoma: Three structurally distinct CDK4/6 inhibitors have recently been licenced for breast cancer treatment: palbociclib, ribociclib and abemaciclib (Knudsen & Witkiewicz, 2017; Alvarez‐Fernandez & Malumbres, 2020).